AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials

UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced the launch of an innovative mobile vision testing program to conduct follow-up assessments during the COVID-19 pandemic for patients enrolled in the Company’s ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).

“We recognize the incredible commitment patients make when they enroll in our trials and our goal is to match that commitment and support them in any way possible,” said Sue Washer, president and CEO of AGTC. “Our highest priority is patients and their safety. During the COVID-19 crisis, patients may be less inclined or find it harder to receive in-person follow-up appointments, an important aspect of assessing the safety and efficacy of the therapy. By using a creative patient-focused approach to testing via our mobile vision testing program, we “take the test to the patient” to support their needs during this extremely difficult time.”

Learn more about AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials.